688192 迪哲医药-U
午间休市 08-07 11:29:59
资讯
新帖
简况
迪哲医药（688192）披露召开2026年第三次临时股东会的通知，8月4日股价上涨1.68%
证券之星 · 08-04 22:17
迪哲医药（688192）披露召开2026年第三次临时股东会的通知，8月4日股价上涨1.68%
每周股票复盘：迪哲医药（688192）与阿斯利康签署授权许可协议
证券之星 · 08-02
每周股票复盘：迪哲医药（688192）与阿斯利康签署授权许可协议
迪哲医药（688192）披露与阿斯利康签署授权许可协议暨关联交易议案获通过，7月30日股价下跌4.07%
证券之星 · 07-30
迪哲医药（688192）披露与阿斯利康签署授权许可协议暨关联交易议案获通过，7月30日股价下跌4.07%
每周股票复盘：迪哲医药（688192）获6亿美元首付款
证券之星 · 07-26
每周股票复盘：迪哲医药（688192）获6亿美元首付款
迪哲医药(688192.SH)发预亏，预计半年度归母净亏损2.1亿元左右
智通财经 · 07-23
迪哲医药(688192.SH)发预亏，预计半年度归母净亏损2.1亿元左右
新股消息 | 迪哲医药(688192.SH)港股IPO招股书失效
智通财经 · 07-23
新股消息 | 迪哲医药(688192.SH)港股IPO招股书失效
迪哲医药（688192）披露拟与阿斯利康签署舒沃哲®全球许可协议，7月22日股价下跌1.49%
证券之星 · 07-22
迪哲医药（688192）披露拟与阿斯利康签署舒沃哲®全球许可协议，7月22日股价下跌1.49%
每周股票复盘：迪哲医药（688192）与阿斯利康签6亿美元协议
证券之星 · 07-19
每周股票复盘：迪哲医药（688192）与阿斯利康签6亿美元协议
迪哲医药（688192）披露关于与阿斯利康签署授权许可协议暨关联交易的议案，7月15日股价上涨20.01%
证券之星 · 07-15
迪哲医药（688192）披露关于与阿斯利康签署授权许可协议暨关联交易的议案，7月15日股价上涨20.01%
7月15日龙虎榜机构席位买卖详情
南方财经网 · 07-15
7月15日龙虎榜机构席位买卖详情
半年BD狂飙千亿、龙头预增13倍！创新药涨停潮再起
格隆汇 · 07-15
半年BD狂飙千亿、龙头预增13倍！创新药涨停潮再起
迪哲医药-U将获6亿美元预付款及最高9亿美元里程碑付款
美股速递 · 07-14
迪哲医药-U将获6亿美元预付款及最高9亿美元里程碑付款
异动快报：迪哲医药-U（688192）7月14日13点0分触及涨停板
证券之星 · 07-14
异动快报：迪哲医药-U（688192）7月14日13点0分触及涨停板
每周股票复盘：迪哲医药（688192）因股价涨幅偏离值累计达30%登龙虎榜
证券之星 · 07-05
每周股票复盘：迪哲医药（688192）因股价涨幅偏离值累计达30%登龙虎榜
迪哲医药（688192）披露股票交易异常波动公告，7月3日股价上涨11.12%
证券之星 · 07-03
迪哲医药（688192）披露股票交易异常波动公告，7月3日股价上涨11.12%
7月3日迪哲医药（688192）龙虎榜数据：机构净买入5650.21万元，北向资金净卖出5874.22万元
证券之星 · 07-03
7月3日迪哲医药（688192）龙虎榜数据：机构净买入5650.21万元，北向资金净卖出5874.22万元
股市必读：迪哲医药（688192）6月16日董秘有最新回复
证券之星 · 06-17
股市必读：迪哲医药（688192）6月16日董秘有最新回复
每周股票复盘：迪哲医药（688192）舒沃哲III期研究登NEJM
证券之星 · 06-07
每周股票复盘：迪哲医药（688192）舒沃哲III期研究登NEJM
迪哲医药泽弗罗韦一线治疗EGFR Exon20ins NSCLC疗效显著优于化疗
美股速递 · 05-29
迪哲医药泽弗罗韦一线治疗EGFR Exon20ins NSCLC疗效显著优于化疗
迪哲医药公布III期悟空28研究结果：泽弗洛维®（舒沃替尼）一线治疗EGFR Exon 20插入突变非小细胞肺癌疗效优于铂类双药化疗
美股速递 · 05-29
迪哲医药公布III期悟空28研究结果：泽弗洛维®（舒沃替尼）一线治疗EGFR Exon 20插入突变非小细胞肺癌疗效优于铂类双药化疗
加载更多
公司概况
公司名称：
迪哲(江苏)医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-12-10
主营业务：
迪哲(江苏)医药股份有限公司的主营业务是专注于肿瘤、血液系统疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲。公司获第七批国家级专精特新“小巨人”企业认定。此外，公司首款源头创新产品舒沃哲的研发及产业化项目，荣获江苏省科技进步奖一等奖。
发行价格：
52.58
{"stockData":{"symbol":"688192","market":"SH","secType":"STK","nameCN":"迪哲医药-U","latestPrice":55.39,"timestamp":1786073399000,"preClose":52.44,"halted":0,"volume":8204923,"delay":0,"changeRate":0.0563,"floatShares":461000000,"shares":465000000,"eps":-1.4341,"marketStatus":"午间休市","change":2.95,"latestTime":"08-07 11:29:59","open":52.5,"high":55.39,"low":52.2,"amount":443000000,"amplitude":0.0608,"askPrice":55.4,"askSize":19,"bidPrice":55.39,"bidSize":297,"shortable":0,"etf":0,"ttmEps":-1.4341,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786078800000},"marketStatusCode":3,"adr":0,"adjPreClose":52.44,"symbolType":"stock_kcb","openAndCloseTimeList":[[1786066200000,1786073400000],[1786078800000,1786086000000]],"highLimit":57.68,"lowLimit":47.2,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":465165842,"isCdr":false,"pbRate":19.76,"roa":"--","roe":"--","epsLYR":-1.71,"committee":0.737113,"marketValue":25766000000,"turnoverRate":0.0178,"status":0,"floatMarketCap":25547000000},"requestUrl":"/m/hq/s/688192/","defaultTab":"news","newsList":[{"id":"2656855286","title":"迪哲医药（688192）披露召开2026年第三次临时股东会的通知，8月4日股价上涨1.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656855286","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656855286?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:17","pubTimestamp":1785853035,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，迪哲医药报收于50.26元，较前一交易日上涨1.68%，最新总市值为233.79亿元。该股当日开盘50.4元，最高51.9元，最低49.78元，成交额达4.58亿元，换手率为1.96%。近日，迪哲（江苏）医药股份有限公司发布《关于召开2026年第三次临时股东会的通知》。公告显示，公司将于2026年8月20日召开2026年第三次临时股东会，会议采用现场投票与网络投票相结合的方式，股权登记日为2026年8月14日。中小投资者对董事选举议案将单独计票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159938","BK1574","BK1161","09939","BK1515","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656196943","title":"每周股票复盘：迪哲医药（688192）与阿斯利康签署授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2656196943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656196943?lang=zh_cn&edition=full","pubTime":"2026-08-02 03:17","pubTimestamp":1785611830,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，迪哲医药报收于51.05元，较上周的55.6元下跌8.18%。本周，迪哲医药7月27日盘中最高价报57.3元。本周关注点公司公告汇总：迪哲医药股东大会通过与阿斯利康签署授权许可协议的议案，获99.9536%同意票。议案获普通股股东同意票186,456,608股，占比99.9536%，中小投资者同意比例为99.4234%。北京市中伦律师事务所出具法律意见书，确认会议召集、召开程序及表决结果合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200001044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1574","BK1161","688192","09939","159938","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655805121","title":"迪哲医药（688192）披露与阿斯利康签署授权许可协议暨关联交易议案获通过，7月30日股价下跌4.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655805121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655805121?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:17","pubTimestamp":1785421034,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，迪哲医药报收于51.16元，较前一交易日下跌4.07%，最新总市值为237.98亿元。近日，迪哲（江苏）医药股份有限公司召开2026年第二次临时股东会，审议通过《关于与阿斯利康签署授权许可协议暨关联交易的议案》。会议于2026年7月30日以现场和网络投票方式召开，出席会议股东188人，代表表决权40.1024%。议案获普通股股东同意票186,456,608股，占比99.9536%，中小投资者对该议案同意比例为99.4234%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000039620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK0239","BK1574","09939","688192","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654105253","title":"每周股票复盘：迪哲医药（688192）获6亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2654105253","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654105253?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:12","pubTimestamp":1784999531,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，迪哲医药报收于55.6元，较上周的61.42元下跌9.48%。本周，迪哲医药7月22日盘中最高价报65.9元。本周关注点来自业绩披露要点：迪哲医药预计2026年上半年营收5.22亿元，同比增长约47.04%。来自公司公告汇总：迪哲医药拟授予阿斯利康舒沃哲全球独家权利，获6亿美元首付款。来自业绩披露要点：归属于母公司净亏损约2.1亿元，同比减少44.35%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1574","09939","688192","BK1161","BK1515","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653746090","title":"迪哲医药(688192.SH)发预亏，预计半年度归母净亏损2.1亿元左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2653746090","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653746090?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:20","pubTimestamp":1784802006,"startTime":"0","endTime":"0","summary":"预计2026年半年度归属于母公司所有者的扣除非经常性损益后的净亏损2.31亿元左右，同比亏损减少44.90%左右。公司2026年半年度营业收入大幅增长，同时产品研发进展较为顺利，研发投入仍保持较高水平，预计2026年半年度将继续出现归属于母公司所有者的净利润为负的情况，但公司主营业务、核心竞争力没有发生重大不利变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688192","BK1161","BK1515","BK1574","BK0239","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653718648","title":"新股消息 | 迪哲医药(688192.SH)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2653718648","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653718648?lang=zh_cn&edition=full","pubTime":"2026-07-23 10:44","pubTimestamp":1784774673,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迪哲(江苏)医药股份有限公司(简称：迪哲医药(688192.SH))于2026年1月23日所递交的港股招股书满6个月，于2026年7月23日失效，递表时高盛和华泰国际为其联席保荐人。据招股书，迪哲医药是一家处于商业化阶段的生物制药公司，公司的核心治疗领域是肿瘤及血液系统疾病。公司的上市产品舒沃哲®是全球范围内唯一获批用于治疗EGFR 20号外显子插入突变型肺癌的小分子表皮生长因子受体酪氨酸激酶抑制剂。于2023年度、2024年度、2025年截至9月30日止九个月，该公司实现收入分别为9128.9万元、3.6亿元、5.86亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","09939","KCE","REDS","BK1515","BK4588","KCAI","BK1161","159938","BK4585","FRHC","IPOS","BK1574","BK4127","BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653676503","title":"迪哲医药（688192）披露拟与阿斯利康签署舒沃哲®全球许可协议，7月22日股价下跌1.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653676503","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653676503?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:14","pubTimestamp":1784729661,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘，迪哲医药报收于60.86元，较前一交易日下跌1.49%，最新总市值为283.1亿元。该股当日开盘60.1元，最高65.9元，最低60.1元，成交额达11.57亿元，换手率为3.96%。近日，迪哲医药披露公告，拟与阿斯利康签署《许可协议》，授予其全球范围内独家开发、商业化舒沃哲的权利。阿斯利康为公司关联法人，本次交易构成关联交易，但不构成重大资产重组。该事项已获董事会审议通过，尚需提交股东会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688192","159938","BK1574","09939","BK1515","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652237196","title":"每周股票复盘：迪哲医药（688192）与阿斯利康签6亿美元协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2652237196","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652237196?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:31","pubTimestamp":1784395867,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，迪哲医药报收于61.42元，较上周的46.76元上涨31.35%。本周，迪哲医药7月16日盘中最高价报69.58元。来自公司公告汇总：迪哲医药与阿斯利康签署授权许可协议，获6亿美元首付款。公司公告汇总迪哲（江苏）医药股份有限公司与阿斯利康签署《许可协议》，授予其全球范围内独家开发、商业化舒沃哲的权利。迪哲医药发布股票交易异常波动公告，2026年7月13日至15日连续三日收盘价涨幅偏离值累计达30%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09939","688192","BK0239","159938","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651422456","title":"迪哲医药（688192）披露关于与阿斯利康签署授权许可协议暨关联交易的议案，7月15日股价上涨20.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651422456","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651422456?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:23","pubTimestamp":1784107401,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘，迪哲医药报收于67.6元，较前一交易日上涨20.01%，最新总市值为314.45亿元。该股当日开盘62.66元，最高67.6元，最低62.0元，成交额达10.57亿元，换手率为3.42%。迪哲（江苏）医药股份有限公司于近日披露《关于召开2026年第二次临时股东会的通知》。本次会议将审议《关于与阿斯利康签署授权许可协议暨关联交易的议案》，中小投资者将单独计票，关联股东AstraZeneca AB需回避表决。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500032881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159938","BK1515","BK1161","688192","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651567894","title":"7月15日龙虎榜机构席位买卖详情","url":"https://stock-news.laohu8.com/highlight/detail?id=2651567894","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651567894?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:18","pubTimestamp":1784107080,"startTime":"0","endTime":"0","summary":"南财智讯7月15日电，盘后数据显示，因当日异动登上龙虎榜的个股中，34只沪深A股龙虎榜出现了机构的身影，机构合计净买入30394.26万元，具体来看，机构净买入19只个股，净卖出15只个股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607153807534381.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153807534381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0214","BK0094","688192","BK0132","BK0196","002821","BK0125","BK0139","BK0197","BK0217","BK0229","LU1934453819.USD","LU1328615791.USD","BK0239","LU1979443071.USD","BK0121","002558","002185","300821","BK0198","BK0188","603459","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651879434","title":"半年BD狂飙千亿、龙头预增13倍！创新药涨停潮再起","url":"https://stock-news.laohu8.com/highlight/detail?id=2651879434","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651879434?lang=zh_cn&edition=full","pubTime":"2026-07-15 13:50","pubTimestamp":1784094601,"startTime":"0","endTime":"0","summary":"政策密集加码","market":"fut","thumbnail":"https://img3.gelonghui.com/9d73a-d7eab21c-e179-4850-9c4c-edf64e1fd8eb.jpg?guru_height=716&guru_width=1280&guru_size=127989","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/9d73a-d7eab21c-e179-4850-9c4c-edf64e1fd8eb.jpg?guru_height=716&guru_width=1280&guru_size=127989"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5584162","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["002317","BK0070","06978","BK0216","BK0146","688192","BD","BK0239","300149","159992","MEDX","BK0028","BK0188","IBBQ","BK0060","000566","600664","BK0012","BK0077","002940","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168929538","title":"迪哲医药-U将获6亿美元预付款及最高9亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1168929538","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168929538?lang=zh_cn&edition=full","pubTime":"2026-07-14 14:11","pubTimestamp":1784009481,"startTime":"0","endTime":"0","summary":"迪哲医药-U宣布，公司将获得一笔高达6亿美元的预付款，并有望在此基础上获得总计不超过9亿美元的里程碑付款。这一重大财务安排标志着公司核心资产价值获得国际认可，也为后续研发注入了强劲动力。通过灵活而富有前瞻性的支付结构，合作方展现了对其产品管线潜力的坚定信心。此次交易不仅优化了公司的现金流状况，更将助力其加速推进关键临床项目，在全球创新药领域持续深化布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","LU0640478417.SGD","AZN.UK","LU2089283258.USD","LU1496350502.SGD","LU1153584641.USD","688192","LU2355687059.USD","LU0345777659.USD","LU0963555726.SGD","LU1267930573.SGD","SG9999001176.USD","03165","LU1084165304.USD","LU0128525689.USD","LU2237443382.USD","LU0203347892.USD","LU0823399737.USD","LU2539964713.USD","LU0266013472.USD","LU0310800379.SGD","SG9999001176.SGD","LU0920840948.USD","LU0114720955.EUR","LU2114397693.USD","LU2089284900.SGD","LU0827474353.SGD","LU0310799852.SGD","LU1291159041.SGD","LU1814569148.SGD","LU1323610961.USD","LU2112291526.USD","LU2237443549.SGD","LU2293690082.USD","LU1119994496.HKD","LU0203345920.USD","LU1923622614.USD","LU2293690249.USD","IE0002141913.USD","LU0058720904.USD","LU0738911758.USD","LU0972486137.USD","IE00BJT1NW94.SGD","LU1061106388.HKD","LU2089984988.USD","LU0575583348.USD","LU0969580561.USD","LU2324357040.USD","LU1481600234.SGD","LU0211326755.USD","LU0823416689.USD","LU2279689827.SGD","LU0784384876.USD","LU1273509221.SGD","LU2125909593.SGD","LU0857590862.USD","LU2125909247.SGD","LU0784385840.USD","LU0499090636.EUR","LU1078025761.USD","LU2023251221.USD","LU0526926950.USD","LU1057294990.SGD","LU1989771016.USD","LU0432979614.USD","LU2091194634.USD","LU0949170772.SGD","LU0957799991.USD","IE00BJJMRZ35.SGD","LU0997586432.USD","LU1196032939.SGD","SG9999013999.USD","LU0310800965.SGD","LU0011850046.USD","LU0889566641.SGD","LU0158827948.USD","LU2108987350.USD","LU1267930813.SGD","LU0784385170.HKD","LU2468319806.SGD","LU0211327993.USD","LU0964806797.USD","LU1153585028.USD","IE00BKPKM643.USD","LU1481599808.USD","LU2237443895.HKD","LU1046234339.USD","LU1104425308.USD","LU1064927863.SGD","LU1019634622.SGD","LU0661504455.SGD","IE00B2B36J28.USD","LU0345777147.USD","LU0496365809.HKD","LU1301847155.USD","IE00BFTCPJ56.SGD","BK5011","LU2133065610.SGD","LU0545039389.USD","LU1355424745.HKD","IE00B4R5TH58.HKD","LU1003076772.USD","LU1487256676.USD","LU1267930227.SGD","LU1880407132.USD","LU2237443622.USD","BK0239","IE0034235188.USD","LU2357627491.SGD","LU2237443978.SGD","LU0052756011.USD","LU0171276677.USD","LU2433249047.HKD","IE0009355771.USD","LU0976567544.SGD","LU0077335932.USD","LU0211328371.USD","LU0887340254.USD","LU1989772840.SGD","SGXZ57979304.SGD","LU0211326839.USD","LU1003077747.HKD","LU0960981461.USD","LU1261432733.SGD","LU0171293334.USD","LU0949170426.SGD","LU0708994859.HKD","LU0920783379.SGD","LU1989772923.USD","LU0122379950.USD","LU1019632923.USD","LU1051770623.HKD","LU0882574055.USD","LU1829250122.USD","LU1170363599.USD","LU0757432116.USD","LU1983299246.USD","LU0128525929.USD","LU0889565080.SGD","LU0390134368.USD","IE00B3T34201.USD","LU0553294199.USD","LU0029864427.USD","LU1015430645.USD","LU0859254822.USD","LU1023059063.AUD","LU0557290698.USD","LU0047473722.EUR","LU0047473722.SGD","LU0289739699.SGD","LU1880407215.USD","LU0792757196.USD","LU1267930490.SGD","LU1496350171.SGD","LU0997586515.USD","LU0784383803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651168121","title":"异动快报：迪哲医药-U（688192）7月14日13点0分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2651168121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651168121?lang=zh_cn&edition=full","pubTime":"2026-07-14 13:05","pubTimestamp":1784005553,"startTime":"0","endTime":"0","summary":"证券之星7月14日盘中消息，13点0分迪哲医药-U（688192）触及涨停板。其所属行业化学制药目前上涨。领涨股为ST南新。该股为医药，创新药概念热股，当日医药概念上涨1.18%，创新药概念上涨0.62%。7月13日的资金流向数据方面，主力资金净流入2756.39万元，占总成交额6.99%，游资资金净流出1696.3万元，占总成交额4.3%，散户资金净流出1060.08万元，占总成交额2.69%。近5日资金流向一览见下表：迪哲医药-U主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400021347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159938","BK1515","BK1161","688192","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649694872","title":"每周股票复盘：迪哲医药（688192）因股价涨幅偏离值累计达30%登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2649694872","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649694872?lang=zh_cn&edition=full","pubTime":"2026-07-05 01:44","pubTimestamp":1783187055,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，迪哲医药报收于48.48元，较上周的36.49元上涨32.86%。本周，迪哲医药7月3日盘中最高价报49.0元。本周关注点来自交易信息汇总：迪哲医药因连续3个交易日收盘价涨幅偏离值累计达30%登上龙虎榜。公司公告汇总迪哲（江苏）医药股份有限公司股票交易异常波动公告迪哲（江苏）医药股份有限公司股票于2026年7月1日至7月3日连续三个交易日内收盘价格涨幅偏离值累计达到30%，构成股票交易异常波动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1574","BK1515","BK0239","09939","688192","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648661527","title":"迪哲医药（688192）披露股票交易异常波动公告，7月3日股价上涨11.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648661527","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648661527?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:12","pubTimestamp":1783087948,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，迪哲医药报收于48.48元，较前一交易日上涨11.12%，最新总市值为225.51亿元。该股当日开盘44.28元，最高49.0元，最低43.92元，成交额达6.83亿元，换手率为3.19%。近日，迪哲（江苏）医药股份有限公司发布《股票交易异常波动公告》。公告显示，公司股票于2026年7月1日至7月3日连续三个交易日内收盘价格涨幅偏离值累计达到30%，构成股票交易异常波动。董事会确认无应披露而未披露的信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300045550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938","688192","BK1161","BK1574","BK1515","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648650988","title":"7月3日迪哲医药（688192）龙虎榜数据：机构净买入5650.21万元，北向资金净卖出5874.22万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648650988","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648650988?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:44","pubTimestamp":1783071869,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年7月3日公布的交易公开信息显示，迪哲医药因有价格涨跌幅限制的连续3个交易日内收盘价格涨幅偏离值累计达到30%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年7月3日收盘，迪哲医药报收于48.48元，上涨11.12%，换手率3.19%，成交量14.74万手，成交额6.83亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入5650.21万元，北向资金合计净卖出5874.22万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300032979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239","BK1574","BK1515","09939","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644376432","title":"股市必读：迪哲医药（688192）6月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644376432","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644376432?lang=zh_cn&edition=full","pubTime":"2026-06-17 01:57","pubTimestamp":1781632634,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，迪哲医药报收于36.95元，下跌2.58%，换手率1.06%，成交量4.88万手，成交额1.81亿元。董秘最新回复投资者： 尊敬的公司领导：作为一名公司投资者，很关心公司发展。公司正在积极准备向美国食品药品监督管理局递交新增适应症上市申请，后续进展我们将及时进行信息披露告知广大投资者。当日关注点交易信息汇总：6月16日主力资金净流出1532.02万元，游资资金净流入583.04万元，散户资金净流入948.98万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700000777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127364","title":"每周股票复盘：迪哲医药（688192）舒沃哲III期研究登NEJM","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127364","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641127364?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:10","pubTimestamp":1780769425,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，迪哲医药报收于39.49元，较上周的55.53元下跌28.89%。本周，迪哲医药6月1日盘中最高价报57.22元。舒沃哲国际多中心III期研究“悟空28”以口头报告形式发布，并发表于《新英格兰医学杂志》，显示其在EGFR exon20ins NSCLC一线治疗中显著改善无进展生存期和客观缓解率。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184495041","title":"迪哲医药泽弗罗韦一线治疗EGFR Exon20ins NSCLC疗效显著优于化疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1184495041","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184495041?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:54","pubTimestamp":1780059272,"startTime":"0","endTime":"0","summary":"迪哲医药宣布，其核心候选药物泽弗罗韦在一线治疗EGFR Exon20ins非小细胞肺癌的临床试验中，显示出相较于标准化疗方案更优的疗效。这一积极数据进一步验证了该药物在解决这一特定难治性肺癌亚型方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156054701","title":"迪哲医药公布III期悟空28研究结果：泽弗洛维®（舒沃替尼）一线治疗EGFR Exon 20插入突变非小细胞肺癌疗效优于铂类双药化疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1156054701","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156054701?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:53","pubTimestamp":1780059200,"startTime":"0","endTime":"0","summary":"迪哲医药宣布，其III期临床研究“悟空28”取得积极结果。数据显示，该公司核心产品泽弗洛维®（舒沃替尼）作为一线疗法，在治疗携带EGFR Exon 20插入突变的非小细胞肺癌患者时，其疗效显著优于标准的铂类双药化疗方案。这一关键性研究成果为这类难治性肺癌患者提供了新的、更具潜力的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786074482556,"stockEarnings":[{"period":"1week","weight":0.025},{"period":"1month","weight":0.1348},{"period":"3month","weight":-0.0346},{"period":"6month","weight":-0.0106},{"period":"1year","weight":-0.3031},{"period":"ytd","weight":-0.0896}],"compareEarnings":[{"period":"1week","weight":0.0251},{"period":"1month","weight":-0.0225},{"period":"3month","weight":-0.0669},{"period":"6month","weight":-0.0406},{"period":"1year","weight":0.0733},{"period":"ytd","weight":-0.0173}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迪哲(江苏)医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10895人(较上一季度增加8.82%)","perCapita":"42332股","listingDate":"2021-12-10","address":"江苏省无锡市新吴区和风路26号汇融商务广场C栋404、405、416室","registeredCapital":"46516万元","survey":" 迪哲(江苏)医药股份有限公司的主营业务是专注于肿瘤、血液系统疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲。公司获第七批国家级专精特新“小巨人”企业认定。此外，公司首款源头创新产品舒沃哲的研发及产业化项目，荣获江苏省科技进步奖一等奖。","listedPrice":52.58},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪哲医药-U(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪哲医药-U(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪哲医药-U,688192,迪哲医药-U股票,迪哲医药-U股票老虎,迪哲医药-U股票老虎国际,迪哲医药-U行情,迪哲医药-U股票行情,迪哲医药-U股价,迪哲医药-U股市,迪哲医药-U股票价格,迪哲医药-U股票交易,迪哲医药-U股票购买,迪哲医药-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪哲医药-U(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪哲医药-U(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}